Print Page   |   Sign In   |   Join!
HOD Feedback for Pennsylvania ASHP Members
1
| 2
>
>|
Forum Actions

Topics   Replies Score Author Latest Post
March 2018COT: Appropriate Dosing of Medications in Patient Populations wit 0 B. O'Hara To discontinue ASHP policy 0228, Appropriate Dosing of Medications in Patient Populations with Unique Needs, which reads:  To advocate reforms in medication-use systems, including electronic systems, and healthcare provider education and training that facilitate optimal patient-specific dosing in populations of patients with altered pharmacokinetics and pharmacodynamics.
by B. O'Hara
Monday, March 5, 2018
March 2018COT: Drug Dosing in Conditions that Modify Pharmacokinetics or Ph 0 B. O'Hara To encourage research on the pharmacokinetics and pharmacodynamics of drugs in acute and chronic conditions; further,   To advocate healthcare provider education and training that facilitate optimal patient-specific dosing in populations of patients with altered pharmacokinetics and pharmacodynamics; further,  To support development and use of standardized models, laboratory assessment, genomic testing, utilization biomarkers, and electronic health record documentation of pharmacokinetic and pharmacodynamic changes in acute and chronic conditions; further,  To collaborate with stakeholders in enhancing aggregation and publication of and access to data on the effects of such pharmacokinetic and pharmacodynamic changes on drug dosing within these patient populations.  (Note: This policy would supersede ASHP policy 1720.) 
by B. O'Hara
Monday, March 5, 2018
March 2018 CPuP: Size, Color, and Shape of Drug Products 0 B. O'Hara To discontinue ASHP policy 8310, Size, Color, and Shape of Drug Products, which reads as follows:  To approve the authority of manufacturers to copy the size, shape, and color of generically equivalent drug products as a means of promoting better patient compliance (rational drug therapy), but only when the source and identity of the product are readily ascertainable from a uniform mark or symbol on the product.
by B. O'Hara
Monday, March 5, 2018
March 2018CPuP: Confidence in the U.S. Drug Approval and Regulatory Process 0 B. O'Hara To support and foster legislative and regulatory initiatives designed to improve public and professional confidence in the drug approval and regulatory process in which all relevant data are subject to public scrutiny.  (Note: This policy would supersede ASHP policy 9010.)
by B. O'Hara
Monday, March 5, 2018
March 2018 CPhP: Role of Pharmacists and Business Leaders in Health Care Se 0 B. O'Hara To discontinue ASHP policy 9819, Role of Pharmacists and Business Leaders in Health Care Services and Policies, which reads:  To support the principle that business leaders and health professionals must share responsibility and accountability for providing optimal health care services to patients; further,  To support the principle that business leaders should expect practicing pharmacists to formulate policies that affect the prerogative of pharmacists to make optimal care decisions on behalf of patients.
by B. O'Hara
Monday, March 5, 2018
March 2018 CPhP: Medications Derived from Biologic Sources 0 B. O'Hara To discontinue ASHP policy 0809, Medications Derived from Biologic Sources, which reads:  To encourage pharmacists to take a leadership role in their health systems for all aspects of the proper use of medications derived from biologic sources, including preparation, storage, control, distribution, administration procedures, safe handling, and therapeutic applications; further,  To facilitate education of pharmacists about the proper use of medications derived from biologic sources.  (Note: Section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] defines biological product as follows: a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, or arsphenamine or derivative of arsphenamine [or any other trivalent organic arsenic compound], applicable to the prevention, treatment, or cure of a disease or condition of human beings.)
by B. O'Hara
Monday, March 5, 2018
March 2018 CPM: Gene Therapy 0 B. O'Hara To assert that health-system decisions on the selection, use, and management of gene therapy agents should be managed as part of the medication formulary system in that (1) decisions are based on clinical, ethical, legal, social, philosophical, quality-of-life, safety, comparative effectiveness , and pharmacoeconomic factors that result in optimal patient care; and (2) such decisions must include the active and direct involvement of physicians, pharmacists, and other appropriate healthcare professionals; further,  To advocate that gene therapy be documented in the permanent patient health record; further,  To advocate that documentation of gene therapy in the permanent patient health record accommodate documentation by all healthcare team members, including pharmacists.  (Note: This policy would supersede ASHP policy 0103.)
by B. O'Hara
Monday, March 5, 2018
March 2018 CPM: Unit Dose Packaging Availability 0 B. O'Hara To advocate that pharmaceutical manufacturers provide all medications used in health systems in unit dose packages or, when applicable, in packaging that reduces medication waste; further, To urge the Food and Drug Administration to support this goal in the interest of public health and healthcare worker and patient safety. (Note: This policy would supersede ASHP policy 0309.)
by B. O'Hara
Monday, March 5, 2018
March 2018 CEWD: Pharmacy Practice Training Models 0 B. O'Hara To promote pharmacy practice training models that: (1) provide experiential and residency training in interprofessional patient care; (2) use the knowledge, skills, and abilities of student pharmacists and residents in providing direct patient care; (3) promote use of the pharmacist layered learning model; further,  To support the assessment of the impact of these pharmacy practice training models on the quality of learner experiences and patient care outcomes.  (Note: This policy would supersede ASHP policy 1316.) 
by B. O'Hara
Monday, March 5, 2018
June HOD CPhP 2. Integrated Approach for the Pharmacy Enterprise 1 W. O'Hara On behalf of the Council for Pharmacy Practice, we met to discuss the proposed amendment.  We are supportive of the amendment as written.  To further support the recommended language we recommend  changes to the rationale to ensure the reader understands the terminology of “pharmacy enterprise” and what that encompasses.  During policy week we wanted to ensure that with expanding health care systems we recognized that the enterprise not only included also pharmacists that may function under other service lines across the system as well (reporting to a medical service or perhaps laboratory service like in pharmacogenomics).  The proposed amendment before the HOD would be as follows: To advocate that pharmacy department leaders promote an integrated  approach for all pharmacy personnel  involved in the medication-use process; further,   To advocate a high level of coordination of all components of the pharmacy enterprise across the continuum of care for the purpose of optimizing (1) medication-use safety, (2) quality, (3) outcomes, and (4)   drug therapy; further, The Council will work together with Dr. Scott Knoer to bring the amendment before the House at the June 2016 meeting.  Thank you in advance ------------------------------ Julie Groppi FASHP Chair, ASHP Council for Pharmacy Practice 2015-16
by B. O'Hara
Wednesday, May 25, 2016
June HOD CPhP 3. Preventing Exposure to Allergens 1 W. O'Hara Latest update from ASHP COnnectOn behalf of the Council for Pharmacy Practice, we met to discuss the recommendations and amending language brought forth by Dr. Kristi Gullickson, Dr. Casey White, Dr. Arlene Iglar and Mr. Jamie Sinclair. Council members agreed in concept with the amending language but recommended a different term could be used rather than “solicitation”. In working with the delegates we agreed on replacing the terminology of "solicitation" with "collection". When the Council initially crafted the language for this policy statement, we intended that “assessment and documentation” to include the act of the obtaining the initial list and/or verifying the final list of allergens from the patient but agree that adding the language of "collection" helps to clarify the intent. In addition, we are in agreement regarding the need for education of all pharmacy staff to include pharmacists and pharmacy technicians. We initially intended the term "professional" to encompass the pharmacy technician but realize that the broader term of "personnel" is more readily understood to include technicians. The amending policy before the HOD would be as follows: To advocate for pharmacy participation in the collection, assessment and documentation of a complete list of allergens pertinent to medication therapy, including food, excipients, medications, devices, and supplies, and any other relevant personal or environmental factor, for the purpose of clinical decision-making; further, To advocate that vendors of medication-related databases incorporate and maintain information about medication-related allergens and cross-sensitivities; further, To advocate that pharmacy professional personnel actively review allergens pertinent to medication therapy and minimize patient and healthcare worker exposure to known allergens, as feasible; further, To encourage pharmacist pharmacy personnel education on medication-related allergens.The Council is supportive of the proposed amendment and language changes. Thank you for the careful consideration of this policy recommendation. ------------------------------Julie Groppi PharmD, FASHPChair, Council for Pharmacy Practice 2015-16
by B. O'Hara
Wednesday, May 25, 2016
June HOD COT 5. Use of Methadone to Treat Pain 0 W. O'Hara To acknowledge that methadone has a role in pain management and that its pharmacologic properties present unique risks to patients; further,  To oppose the use of methadone as a preferred treatment option for acute and chronic pain; further,  To advocate that all healthcare practitioners who prescribe or dispense methadone complete a standardized educational program specific to the drug; further,  To advocate that pain management experts, payers, and manufacturers collaborate to provide educational programs for healthcare professionals on treating acute and chronic pain with opioids, including methadone; further,  To advocate that all facilities that dispense methadone, including addiction treatment programs, participate in state prescription drug monitoring programs. --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD COT 6. Therapeutic Indication of Prescribing 0 W. O'Hara To advocate that healthcare organizations optimize use of clinical decision support systems by structuring them to include the indication for high-risk and problem-prone medications. --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD COT 1. Stewardship of Drugs with Potential for Abuse 0 W. O'Hara To encourage stewardship of drugs with potential for abuse; further,  To facilitate the development of best practices for prescription drug monitoring programs and drug take-back disposal programs for drugs with potential for abuse.  --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy." ------------------------------ Amber J Lucas, PharmD, BCPS, FASHP Clinical Pharmacist Olathe Medical Center 20333 W. 151st St. Olathe, KS 66061 913-791-4287 ------------------------------
by W. O'Hara
Sunday, May 15, 2016
June HOD COT 2. Appropriate Use of Antipsychotic Drug Therapies 0 W. O'Hara   To advocate for the documentation of appropriate indication and goals of therapy to promote the judicious use of antipsychotic drugs and reduce the potential for harm; further,  To support the participation of pharmacists in the management of antipsychotic drug use, which is an interdisciplinary, collaborative process for selecting appropriate drug therapies, educating and monitoring patients, continually assessing outcomes of therapy, and identifying appropriate discontinuation; further, To advocate that pharmacists lead efforts to prevent inappropriate use of antipsychotic drugs, including engaging in strategies to detect and address patterns of use in patient populations at increased risk for adverse outcomes. --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD COT 3. Safety of Epidural Steroid Injections 0 W. O'Hara To encourage healthcare providers to 1) inform patients about the significant risks associated with epidural steroid injections, and 2) request their informed consent; further,  To encourage healthcare organizations to prevent adverse events related to epidural steroid injections by having pharmacists involved in the development of protocols that promote the safe use of such injections.  --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."  
by W. O'Hara
Sunday, May 15, 2016
June HOD CEWD 3. Developing Leadership Competencies 0 W. O'Hara To work with healthcare organization leadership to foster opportunities, allocate time, and provide resources for pharmacy practitioners to move into leadership roles; further,  To encourage leaders to seek out and mentor pharmacy practitioners in developing administrative, managerial, and leadership skills; further,  To encourage pharmacy practitioners to obtain the skills necessary to pursue administrative, managerial, and leadership roles; further,  To encourage colleges of pharmacy and ASHP state affiliates to collaborate in fostering student leadership skills through development of co-curricular leadership opportunities, leadership conferences, and other leadership promotion programs; further,  To reaffirm that residency programs should develop leadership skills through mentoring, training, and leadership opportunities; further,  To foster leadership skills for pharmacists to use on a daily basis in their roles as leaders in patient care.  (Note: This policy would supersede ASHP policy 1518.)  --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD CEWD 5. Cultural Competency and Cultural Diversity 0 W. O'Hara To endorse the development of cultural competency of pharmacy educators, practitioners, residents, students, and technicians; further,  To educate providers on the importance of providing culturally congruent care to achieve quality care and patient engagement; further,  To advocate for an ethnically and culturally diverse workforce.  (Note: This policy would supersede ASHP policy 1414.)  --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD CPM 1. Controlled Substance Diversion and Patient Access 0 W. O'Hara To enhance awareness by pharmacists, healthcare providers, and the public of drug diversion and abuse of controlled substances; further,  To advocate that pharmacists take a leadership role in national efforts to reduce the incidence of controlled substance abuse; further,  To advocate that pharmacists lead collaborative efforts by organizations of healthcare professionals, patient advocacy organizations, and regulatory authorities to develop and promote best practices for preventing drug diversion and appropriately using controlled substances to optimize patient access and therapeutic outcomes; further,  To advocate that the Drug Enforcement Administration and other regulatory authorities interpret and enforce laws, rules, and regulations to support patient access to appropriate therapies, minimize burdens on pharmacy practice, and provide reasonable safeguards against fraud, misuse, abuse, and diversion of controlled substances; further,  To encourage healthcare organizations to establish programs to support patients and personnel with substance abuse and dependency issues. --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD CPM 4. Patient Satisfaction 0 W. O'Hara To encourage pharmacists to evaluate their practice settings for opportunities to improve the level of satisfaction patients have with healthcare services and with the outcomes of their drug therapy; further, To educate pharmacists and pharmacy personnel about the relationship between patient satisfaction and positive health outcomes, further, To develop or adopt tools that will (1) provide a system for monitoring trends in the quality of pharmacy services to patients, (2) increase recognition of the value of pharmacy services, and (3) provide a basis for making improvements in the process and outcomes of pharmacy services in efforts to engage patients and improve satisfaction; further, To facilitate a dialogue with and education of national patient satisfaction database vendors on the role and value of clinical pharmacy services. (Note: This policy would supersede ASHP policy 0104.) --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
more Calendar

10/9/2018
BuxMont September Dinner Meeting

Membership Management Software Powered by YourMembership  ::  Legal